J Thromb Haemost - (-) - [2021-07-17; online 2021-07-17]
We acknowledge the commentary of Gruel et al. on our recent letter  and are pleased that the authors agree that IdeS may be a potential treatment option for the rare but potentially severe IgG-mediated platelet activation observed in complications to vaccination with ChAdOx1 nCoV-19. It is apparent that our respective but distinct expertise with regard to IdeS has led us to develop this hypothesis in parallel. As we clearly cited in our original letter these authors have previously contributed important evidence that IdeS may be beneficial in treating IgG-mediated platelet dysfunction in a mouse model of heparin induced thrombocytopenia . The intention with our letter was to provide more background to IdeS and insight into the unique properties of IdeS that make it suitable for treating many manifestations of IgG-mediated human disease.